Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects

Jia, Hong-Ti; Truica, Cristina I.; Wang, Bin; Wang, Yanhong; Ren, Xingcong; Harvey, Harold A.; Song, Jianxun; Yang, Jin Ming

doi:10.1016/j.drup.2017.07.002

Cited by 155 publications

(107 citation statements)

References 146 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Some of these vaccines have been investigated in clinical trials (109). In patients with PD-L1 + TNBC tissues, the overall response rate to ICB therapy ranges from 10 to 18.5% (110). In an ongoing Phase Ib clinical trial, HLA-A2 + Metastatic TNBC is treated using a combination of PVX-410 cancer vaccine and pembrolizumab (NCT03362060).…”

Section: The Preclinical and Clinical Applications Of Lncrnas In Cancmentioning

confidence: 99%

Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment

Luo

Yang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Section: The Preclinical and Clinical Applications Of Lncrnas In Cancmentioning

confidence: 99%

Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment

Luo

Yang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

“…Recently, many studies have found that inflammation and immunity play critical roles in tumor initiation, invasion, and metastasis [6]. Host anti-tumor immunity might offer a new strategy for curing BC [7][8][9]. The basic immune surveillance of the body and changes in systemic immune status, affect responses to therapy and even prognosis of BC patients.…”

Section: Introductionmentioning

confidence: 99%

“…The basic immune surveillance of the body and changes in systemic immune status, affect responses to therapy and even prognosis of BC patients. Nevertheless, there are no authorized biomarkers reflecting systemic immune status [8]. Some studies indicated that low pretreatment neutrophil/lymphocyte ratio (NLR) was predictive factor of better DFS outcome in BC, especially in triplenegative BC patients [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Ding

Huang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: The relationship of neutrophil/lymphocyte ratio (NLR) to prognosis of HER2-positive breast cancer (BC) is not well studied. We aimed to assess the prognostic role of NLR in HER2-positive BC patients treated with or without trastuzumab. Methods: The clinical data of 843 HER2-positive BC patients from July 2013 to July 2018 were collected. The difference among variables was calculated by chi-square test. The associations between clinicopathological factors, NLR and disease-free survival (DFS) were analyzed by univariate and multivariate analyses. Results: Patients were divided into three groups. In group 1 containing 255 patients without trastuzumab treatment, pretreatment NLR showed no predictive value. Patients with trastuzumab treatment were divided into two groups on equal, according to pretreatment NLR values, low NLR (group 2) and high NLR (group 3). Patients in group 2 showed significantly higher 3-year DFS rate than patients in group 1 and group 3 (95.3% vs. 91.6% vs. 90.5%, respectively, P = 0.011); patients in the group 1 and group 3 had a similar 3-year DFS outcome. Multivariate analysis showed high pretreatment NLR was significantly associated with shorter DFS (HR = 2.917, 95% CI = 1.055-8.062, P = 0.039) in HER2-positive BC patients treated with trastuzumab. Conclusions: Among HER2-positive trastuzumab-treated BC patients, low pretreatment NLR value was associated with better DFS, and it might help to differentiate potential beneficiaries of trastuzumab treatment.

show abstract

“…Recently, many studies have found that inflammation and immunity play critical roles in tumor initiation, invasion, and metastasis [16]. Host anti-tumor immunity might offer a new strategy for curing BC [18,26,32]. The basic immune surveillance of the body and changes in systemic immune status, affect responses to therapy and even prognosis of BC patients.…”

Section: Introductionmentioning

confidence: 99%

“…The basic immune surveillance of the body and changes in systemic immune status, affect responses to therapy and even prognosis of BC patients. Nevertheless, there are no authorized biomarkers reflecting systemic immune status [18]. Some studies indicated that low pretreatment neutrophil/lymphocyte ratio (NLR) was predictive factor of better DFS outcome in BC, especially in triple-negative BC patients [1,4,13].…”

Section: Introductionmentioning

confidence: 99%

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Ding

Huang

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose: The relationship of neutrophil/lymphocyte ratio (NLR) with prognosis of HER2-positive breast cancer (BC) are not well studied. We aimed to assess the prognostic role of NLR in HER2-positive BC patients treated with or without trastuzumab.Methods: The clinical data of 843 HER2-positive BC patients from July 2013 to July 2018 were collected. The difference among variables was calculated by chi-square test. The associations between clinicopathological factors, NLR and disease-free survival (DFS) were analyzed by univariate and multivariate analyses.Results : Patients were divided into three groups. In group 1 containing 255 patients without trastuzumab treatment, pretreatment NLR showed no predictive value. Patients with trastuzumab treatment were divided into two groups on equal, according to pretreatment NLR values, low NLR (group 2) and high NLR (group 3). Patients in group 2 showed significantly higher 3-year DFS rate than patients in group 1 and group 3 (95.3% vs. 91.6% vs. 90.5%, respectively, P = 0.011); patients in the group 1 and group 3 had similar 3-year DFS outcome. Multivariate analysis showed high pretreatment NLR was significantly associated with shorter DFS (HR = 2.917, 95% CI=1.055-8.062, P = 0.039) in HER2-positive BC patients treated with trastuzumab. Conclusion : Among HER2-positive trastuzumab-treated BC patients, low pretreatment NLR value was associated with better DFS, and it might help to differentiate potential beneficiaries of trastuzumab treatment.

show abstract

Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects

Cited by 155 publications

References 146 publications

Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment

Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Contact Info

Product

Resources

About